Your browser doesn't support javascript.
loading
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19
Simon P Graham; Rebecca K McLean; Alexandra J Spencer; Sandra Belij-Rammerstorfer; Daniel Wright; Marta Ulaszewska; Jane C Edwards; Jack W P Hayes; Veronica Martini; Nazia Thakur; Carina Conceicao; Isabelle Dietrich; Holly Shelton; Ryan Waters; Anna Ludi; Ginette Wilsden; Clare Browning; Dagmara Bialy; Sushant Bhat; Phoebe Stevenson-Leggett; Philippa Hollinghurst; Ciaran Gilbride; David Pulido; Katy Moffat; Hannah Sharpe; Elizabeth Allen; Valerie Mioulet; Chris Chiu; Joseph Newman; Amin S Asfor; Alison Burman; Sylvia Crossley; Jiandong Huo; Raymond J Owens; Miles Carroll; John A Hammond; Elma Tchilian; Dalan Bailey; Bryan Charleston; Sarah C Gilbert; Tobias J Tuthill; Teresa Lambe.
Afiliación
  • Simon P Graham; The Pirbright Institute
  • Rebecca K McLean; The Pirbright Institute
  • Alexandra J Spencer; University of Oxford
  • Sandra Belij-Rammerstorfer; University of Oxford
  • Daniel Wright; University of Oxford
  • Marta Ulaszewska; University of Oxford
  • Jane C Edwards; The Pirbright Institute
  • Jack W P Hayes; The Pirbright Institute
  • Veronica Martini; The Pirbright Institute
  • Nazia Thakur; The Pirbright Institute
  • Carina Conceicao; The Pirbright Institute
  • Isabelle Dietrich; The Pirbright Institute
  • Holly Shelton; The Pirbright institute
  • Ryan Waters; The Pirbright Institute
  • Anna Ludi; The Pirbright Institute
  • Ginette Wilsden; The Pirbright Institute
  • Clare Browning; The Pirbright Institute
  • Dagmara Bialy; The Pirbright Institute
  • Sushant Bhat; The Pirbright Institute
  • Phoebe Stevenson-Leggett; The Pirbright Institute
  • Philippa Hollinghurst; The Pirbright Institute
  • Ciaran Gilbride; University of Oxford
  • David Pulido; University of Oxford
  • Katy Moffat; The Pirbright Institute
  • Hannah Sharpe; University of Oxford
  • Elizabeth Allen; University of Oxford
  • Valerie Mioulet; The Pirbright Institute
  • Chris Chiu; The Pirbright Institute
  • Joseph Newman; The Pirbright Institute
  • Amin S Asfor; The Pirbright Institute
  • Alison Burman; The Pirbright Institute
  • Sylvia Crossley; The Pirbright Institute
  • Jiandong Huo; University of Oxford
  • Raymond J Owens; University of Oxford
  • Miles Carroll; Public Health England
  • John A Hammond; The Pirbright Institute
  • Elma Tchilian; The Pirbright Institute
  • Dalan Bailey; The Pirbright Institute
  • Bryan Charleston; The Pirbright Institute
  • Sarah C Gilbert; University of Oxford
  • Tobias J Tuthill; The Pirbright Institute
  • Teresa Lambe; University of Oxford
Preprint en Inglés | bioRxiv | ID: ppbiorxiv-159715
Artículo de revista
Un artículo publicado en revista científica está disponible y probablemente es basado en este preprint, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver artículo de revista
ABSTRACT
Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.
Licencia
cc_by_nc_nd
Texto completo: Disponible Colección: Preprints Base de datos: bioRxiv Tipo de estudio: Experimental_studies / Estudio pronóstico Idioma: Inglés Año: 2020 Tipo del documento: Preprint
Texto completo: Disponible Colección: Preprints Base de datos: bioRxiv Tipo de estudio: Experimental_studies / Estudio pronóstico Idioma: Inglés Año: 2020 Tipo del documento: Preprint
...